New Tool Can Predict Alzheimer’s Better Than Genetic Variant APOE E4 Alone, Study Finds

New Tool Can Predict Alzheimer’s Better Than Genetic Variant APOE E4 Alone, Study Finds
A new test developed by researchers at UC San Francisco and UC San Diego can better predict which cognitively normal adults will develop Alzheimer's dementia later in life than testing for the well-known genetic variant APOE E4 alone, according to a new study. The study, titled “Polygenic hazard scores in preclinical Alzheimer disease,” was published in the Annals of Neurology. APOE E4 is the most thoroughly researched gene variant known to be associated with Alzheimer’s disease, but only 10 to 15 percent of people at risk of developing the disease carry the variant. Some studies even suggest that its effects as a disease predictor may be overestimated. As a result, a more powerful test was needed to help determine the risk of developing Alzheimer’s. Through the use of genetic data from 70,000-plus people in the NACC (National Alzheimer’s Coordinating Center), the International Genomics of Alzheimer’s Disease Project, and the Alzheimer’s Disease Genetics Consortium database, researchers were able to identify 31 genetic variants, in addition to APOE E4, that could be used to effectively provide risk estimates for developing Alzheimer's dementia. This data allowed researchers to develop the PHS (polygenic hazard score) test, which can calculate age-specific risk estimates of developing Alzheimer's disease. The PHS combines 31 genetic variants that were individually discovered to be as
Subscribe or to access all post and page content.

One comment

  1. Denise says:

    Looking for any information regarding gene splicing to reprogram DNA to treat/cure Alzheimer’s. Studies or trials, past or present.

Leave a Comment

Your email address will not be published. Required fields are marked *